109: Aurobindo's US outlook improves but earnings may just be steady

Investors are banking on Aurobindo’s US pharma revenues getting a boost on the back of improving injectable sales in the second quarter. But a part of that growth already seems to be reflecting in the stock price gains of about 86% in 2020. Find more details in this podcast. Listen in.

132 Episodes

22 Dec 2024

62: RBI stress tests show a grim asset quality outlook for banks

6 MINS

22 Dec 2024

61: ICICI Pru life Fares Better In Q1 Whereas SBI Life & HDFC Life Show Lockdown Impact

6 MINS

22 Dec 2024

60: With no bailout, how are India's domestic airlines surviving?

7 MINS

22 Dec 2024

59: Yes Bank gets a second chance at survival

6 MINS

22 Dec 2024

58: Key takeaways from RIL's AGM and implications for the stock

6 MINS

22 Dec 2024

57: DMart Q1FY21 profit almost vanishes; stock now trades at 140 times earnings

7 MINS

22 Dec 2024

56: Why TCS investors should not mimic those of Accenture?

6 MINS

22 Dec 2024

55: Titan’s recovery in June comforts but stock’s valuations are shimmering already

6 MINS

22 Dec 2024

54: Even as IndusInd, Federal Bank feel COVID blues in Q1FY21, HDFC Bank shows loan growth

6 MINS

22 Dec 2024

53: HDFC and group companies may eye acquisitions amid COVID-19

6 MINS

< 1 … 6 7 8 9 10 … 14 >